Eaton’s Vehicle Group and eMobility Continue to Expand Footprint in Europe to Support Growth of Electrified Vehicle Market
26.4.2022 13:30:00 EEST | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group and eMobility businesses are continuing their expansion into Europe, a leading region in electrified vehicle (EV) technology, with the establishment of a new office and research center in Karlsruhe, Germany. This expansion will complement existing engineering and manufacturing sites in Montrottier, France, and Tczew, Poland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005305/en/
Eaton eMobility engineer inspects a high-voltage traction inverter for electric vehicles. (Photo: Business Wire)
The new office in Karlsruhe will serve as a base for customer interaction and engineering service for Eaton’s Vehicle Group and eMobility customers in the region. The facility will include a new laboratory that enables rapid turnaround in testing Eaton’s latest eMobility products.
“The city of Karlsruhe is a central location in Europe near major automotive manufacturers and suppliers, allowing us to be closer to our customers and satisfy their needs in terms of research and development,” said Scott Adams, president, eMobility, Eaton. “The new facility is also close to several prestigious universities, which will allow us to attract talent for our research center.’’
This location will also host Vehicle Group employees from varying product lines and functions, ensuring an integrated approach and alignment with customers across the region.
Eaton is also expanding and upgrading its engineering and manufacturing capacity across its other sites in the region.
The Vehicle Group’s recent expansion of its Tczew facility includes investing more than $20 million (USD) to add an innovative laboratory and three new automated production lines to manufacture EV components for its eMobility customers.
Equipment for the new eMobility lines is currently being installed, with the start of production scheduled for the first quarter of 2023. The lines will initially produce traction inverters for a major European automaker that will save energy and help increase the range of EVs and contribute to extended battery life. Additional eMobility solutions will later be produced at the plant, including power distribution units.
In addition, Eaton’s eMobility location in Montrottier is undergoing expansion to support the demand for power electronics and power distribution products for EVs in the automotive sector. Due to its location, the Montrottier plant serves both European-based vehicle manufacturers and suppliers, as well as global customers.
Three new assembly lines will increase output at the facility up to four times that of current levels, and a new cleanroom will allow for testing in a sterile environment. Eaton also will be adding engineering, manufacturing, and support staff to sustain increased production.
“Eaton’s continued expansion in Europe is a crucial step to growing the traditional Vehicle and eMobility businesses and offering cutting-edge EV solutions to our global customers across the region,” said Marco Martini, president, Vehicle Group, Europe, Middle East and Africa (EMEA), Eaton. “These upgrades will support Eaton’s efforts in delivering electric vehicle solutions to passenger car, commercial vehicle and off-highway OEMs globally.”
Eaton’s Vehicle Group and eMobility businesses continue to seek talent for growing global teams. Learn more about opportunities with Eaton’s eMobility.
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005305/en/
Contact information
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 13:45:00 EET | Press release
TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its dealer network, aftersales capabilities and customer support infrastructure across key markets. In Italy, its first European market, TVS now works with around 100 dealers. Retail sales in Italy are up 110% this year to Septem
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom